How a Global Network Accelerated the Development of a Virus-Like Particle Vaccine Against Covid-19

by Ute Boronowsky | February 28, 2022

How a Global Network Accelerated the Development of a Virus-Like Particle Vaccine Against Covid-19

Setting up the logistics and cold chain infrastructure needed for vaccine deployment is expensive and cumbersome, contributing to low vaccination rates in African countries. Enabling local vaccine manufacturing in sufficient quantities and consistent quality could have a significant impact in fighting infectious diseases, including the Covid-19 pandemic.

A partnership between the biotech companies TechnoVax in the US, MilliporeSigma*, and Innovative Biotech in Nigeria aims to empower vaccine development in Africa. Innovative Biotech has developed vaccines against Ebola and HIV, and with the onset of the Covid-19 pandemic, the company quickly switched to the new target.

Learn More about this online article HERE.

Register now for the free on-demand webinar HERE.

* MilliporeSigma is the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany

[starbox id=”UteBoronowsky”]

Ute Boronowsky

Ute Boronowsky obtained a PhD in plant biochemistry at the Ruhr-University Bochum in 1999. After her postdoc at UCLA, she moved to the biotech industry and worked in various sales and marketing positions. Since 2015, she works as a freelance science and marketing writer, translator, and journalist. LinkedIn: